Telomir Financial Statements From 2010 to 2024

TELO Stock   4.91  0.03  0.61%   
Telomir Pharmaceuticals, financial statements provide useful quarterly and yearly information to potential Telomir Pharmaceuticals, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Telomir Pharmaceuticals, financial statements helps investors assess Telomir Pharmaceuticals,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Telomir Pharmaceuticals,'s valuation are summarized below:
Market Capitalization
147 M
Earnings Share
(0.78)
We have found thirty-seven available fundamental trend indicators for Telomir Pharmaceuticals, Common, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Telomir Pharmaceuticals,'s current fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Telomir Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telomir Pharmaceuticals,'s main balance sheet or income statement drivers, such as Selling General Administrative of 724.7 K, Total Revenue of 0.0 or Other Operating Expenses of 4.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 63.3. Telomir financial statements analysis is a perfect complement when working with Telomir Pharmaceuticals, Valuation or Volatility modules.
  
Check out the analysis of Telomir Pharmaceuticals, Correlation against competitors.

Telomir Pharmaceuticals, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Short and Long Term Debt Total86.4 K90.9 K144.9 K
Pretty Stable
Other Current Liabilities636.8 K606.5 K203.7 K
Slightly volatile
Total Current Liabilities901.9 K1.5 M418.6 K
Slightly volatile
Net Debt85.3 K89.8 K144.6 K
Pretty Stable
Accounts Payable414.4 K813.3 K169.7 K
Slightly volatile
Common Stock Shares Outstanding23.7 M26.6 M29 M
Slightly volatile
Other Stockholder Equity21.1 M20.1 MM
Slightly volatile
Total Liabilities901.9 K1.5 M418.6 K
Slightly volatile
Short Term Debt86.4 K90.9 K144.9 K
Pretty Stable
Non Currrent Assets Other5.2 MMM
Slightly volatile
Cash And Short Term Investments1.1 K1.1 K1.4 K
Slightly volatile
Liabilities And Stockholders Equity5.8 M5.5 M1.1 M
Slightly volatile
Other Current Assets193.2 K349.6 K94.3 K
Slightly volatile
Net Receivables104 K117 K127.4 K
Slightly volatile
Inventory242.6 K273 K297.2 K
Slightly volatile
Short and Long Term Debt80.8 K90.9 K99 K
Slightly volatile

Telomir Pharmaceuticals, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative724.7 K690.2 K144.3 K
Slightly volatile
Other Operating Expenses4.8 M4.5 MM
Slightly volatile
Research Development929.1 K1.8 M435.9 K
Slightly volatile
Total Operating Expenses4.8 M4.5 MM
Slightly volatile
Cost Of Revenue3.2 M3.5 M3.9 M
Slightly volatile

Telomir Pharmaceuticals, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Working Capital190 K130.9 K68.4 K
Slightly volatile
Total Cash From Financing Activities4.7 M4.4 M982.8 K
Slightly volatile
Depreciation1.3 M1.5 M1.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Payables Turnover4.465.025.463
Slightly volatile
Cash Per Share1.0E-40.00.0
Pretty Stable
Days Payables Outstanding52.3858.9364.1695
Slightly volatile
Income Quality0.280.29530.7664
Slightly volatile
Current Ratio0.340.32590.0872
Slightly volatile
Graham Number1.131.0740.1742
Slightly volatile
Interest Debt Per Share0.06180.05890.0126
Slightly volatile
Debt To Assets0.02010.021210.3499
Slightly volatile
Days Of Payables Outstanding52.3858.9364.1695
Slightly volatile
Ebt Per Ebit2.662.983.2499
Slightly volatile
Effective Tax Rate1.11.151.0167
Slightly volatile
Quick Ratio0.340.32590.0872
Slightly volatile
Cash Ratio0.00139.0E-40.0014
Slightly volatile
Debt Ratio0.02010.021210.3499
Slightly volatile

Telomir Fundamental Market Drivers

Cash And Short Term Investments1231.00

About Telomir Pharmaceuticals, Financial Statements

Telomir Pharmaceuticals, investors utilize fundamental indicators, such as revenue or net income, to predict how Telomir Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-523.6 K-549.8 K
Cost Of Revenue3.5 M3.2 M

Pair Trading with Telomir Pharmaceuticals,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.

Moving against Telomir Stock

  0.64ALVO AlvotechPairCorr
  0.57BMY Bristol Myers SquibbPairCorr
  0.56GILD Gilead SciencesPairCorr
  0.46XAIR Beyond AirPairCorr
  0.39CAH Cardinal HealthPairCorr
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Telomir Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telomir Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telomir Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telomir Pharmaceuticals, Common Stock:
Check out the analysis of Telomir Pharmaceuticals, Correlation against competitors.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.78)
Return On Assets
(2.05)
Return On Equity
(17.53)
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.